

AWARD NUMBER: W81XWH-14-1-0296

TITLE: Microenvironments and Signaling Pathways Regulating Early Dissemination, Dormancy, and Metastasis

PRINCIPAL INVESTIGATOR: John Condeelis

CONTRACTING ORGANIZATION: Albert Einstein College of Medicine
Bronx, NY 10461-1931

REPORT DATE: September 2016

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE		Form Approved OMB No. 0704-0188
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.		
1. REPORT DATE September 2016	2. REPORT TYPE Annual	3. DATES COVERED 09/01/2015 - 8/31/2016
4. TITLE AND SUBTITLE Microenvironments and Signaling Pathways Regulating Early Dissemination, Dormancy, and Metastasis		5a. CONTRACT NUMBER
		5b. GRANT NUMBER W81XWH-14-1-0296
		5c. PROGRAM ELEMENT NUMBER
6. AUTHOR(S) John Condeelis, Julio Aguirre-Ghiso E-Mail:john.condeelis@einstein.yu.edu		5d. PROJECT NUMBER 0010533520
		5e. TASK NUMBER
		5f. WORK UNIT NUMBER
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Albert Einstein College of Medicine 1300 Morris Park Ave LBBY Bronx, NY 10461-1931		8. PERFORMING ORGANIZATION REPORT NUMBER
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSOR/MONITOR'S ACRONYM(S)
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited		
13. SUPPLEMENTARY NOTES N/A		

14. ABSTRACT

We devoted effort to both aims, to optimize methods and publish the first phase of efforts. **SA1** is to understand the intrinsic mechanisms of dissemination by early-progressed cancer cells and how the microenvironment in these primary sites named P-TMEM (**P**rimary **T**umor **M**icroenvironment of **M**etastases) contribute to early dissemination. We now have new data suggesting that a signature of early dissemination markers consisting on HER2^{HI}/p-ATF2^{LO}/E-cadh^{LO} could identify motile early-progressed tumor cells and predict for dissemination. We further show that mammary tissue macrophages and HER2^{HI}/p-ATF2^{LO}/E-cadh^{LO} tumor cells cooperate to disseminate early. This further supports our hypothesis that even in early cancer lesions macrophages and tumor cells assemble with endothelial cells a TMEM structure. We have also made progress in generating a standardized triple staining that captures all these cell types in all tissues and we have used intravital imaging to document intravasation in early cancer lesions (see also partnering PI progress report). Our work revealed that the presence of intraepithelial macrophages in DCIS samples in mouse models or humans could accurately predict dissemination in 70% of the cases of patients with bone marrow DTCs (**D**isseminated **T**umor **C**ells). **SA2** focuses on elucidate how S-TMEM (**S**econdary **T**umor **M**icroenvironment of **M**etastases) contributes to the dormancy phase of early DTCs. We found that early DTCs appear to undergo a p38 independent but TWIST-dependent dormancy in secondary organs revealing a new pathways for dormancy. Our new data also show that depletion of macrophages during early dissemination steps significantly reduces metastasis that develop into the late stages of progression, providing functional support for macrophages in P- and S-TMEM structures in metastasis development. This work is now part of two papers, one accepted for publication in the journal **Nature** and the other under review in **Nature Communications**. Progress has also been made in the sorting protocol to isolate CFP+/HER2+ DTCs from lungs and CTCs in the MMTV-Neu-CFP model and we have also performed single cell RNA-seq which will allow us in the next year to identify the early and late gene signatures in DTCs we proposed in our grant.

15. SUBJECT TERMS

dormancy, early dissemination, EMT, macrophages, TMEM

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
"U"	"U"	"U"	"UU"	6	19b. TELEPHONE NUMBER (include area code)

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18


Table of Contents

	<u>Page</u>
1. Introduction.....	1
2. Body.....	1
3. Key Research Accomplishments.....	1
4. Conclusion.....	1

Title: Microenvironments and Signaling Pathways Regulating Early Dissemination, Dormancy, and Metastasis.

Original Specific Aim 1- To test how ErbB2^{high}/P-p38^{low} Mammary epithelial cells (MECs) assemble primary Tumor Microenvironment of Metastasis structures (P-TMEM) during early dissemination.

SA1.1. Objective: Use intravital imaging and MMTV-ErbB2-CFP, MMTV-PyMT-EGFP-c-fms-CFP transgenic mice and modulation of ErbB2 and p38 signaling to detect P-TMEM function during intravasation of “early” and “late” ErbB2+ MECs.



A- Results – detection of P-TMEM in the MMTV-Her2 model during early stages of cancer: In FY2 we aimed to identify P-TMEM characterized by the interaction of early cancer cells, macrophages and the vascular endothelial cells where TMEM are identified using antibody staining against the TMEM-tumor cell using anti-Mena, the TMEM-endothelial cell using anti-CD31 and the TMEM-macrophage using anti-CD68. TMEM are identified as a structure when all three stained cells are in direct contact. We therefore optimized this triple staining to detect TMEM structures by IHC in collaboration with the Aguirre-Ghiso lab (**Fig.1**). We found that all 3 TMEM cell types could be detected as a triple cell complex in which the cells are in direct contact with each other thereby identifying TMEM in these early lesions. Optimization of this staining will be required to ensure quantitative scoring. Additional staining of epithelial cells and their cell-cell junctions in adjacent sections might help solve the optimization in the future.

We found that P-TMEM structures could be detected as pre-invasive lesions in both non-proliferative 14wk old and proliferative 24wk old MMTV-HER2 mice but were more frequent in proliferative lesions (**Fig.1B**). Non-proliferative structures often contained intra-epithelial macrophages (**Fig.2A**). Interestingly, during those early stages, dissemination rates are low but can be stimulated through the inhibition of p38 signaling (**Fig. 2B**) which results in the activation of an EMT program and enhanced recruitment of macrophages and vascularization (unpublished observation Aguirre-Ghiso lab).

In contrast, in more progressed but still pre-invasive stages (**Fig.1B**; 24wk old MMTV-HER2 glands), P-TMEM structures are frequently found and this is correlated with enhanced early dissemination (Linde et al., under review *Nature Communications* and also see progress report from Partnering PI Aguirre-Ghiso, JA). **Conclusion:** We found that TMEM staining works in the MMTV-HER2 mouse model and that the TMEM structure is present in these early lesions.

B- Imaging early dissemination and P-TMEM in premalignant stages of Her2+ mammary cancer: In the last progress report we showed how we optimized a mammary gland imaging window to perform intravital imaging and detect P-TMEM function during early stages of progression in the MMTV-HER2 model. This work has progressed significantly and we were able to not only document local invasion as in last year's progress report but also document the interaction of early disseminating cancer cells with the vasculature and entry into the vasculature that was corroborated by the detection of circulating cancer cells at this stage and disseminated cancer cells in target organs such as lung and bone marrow. Briefly, in **Fig 2** we show that we have been able to monitor early dissemination using high-resolution intra-vital imaging¹⁴ of MMTV-Her2-CFP transgenic mice (**Fig2**). Using a new mammary imaging window and 2-photon imaging in vehicle treated Her2-CFP mice¹⁴ we found that while at 10 weeks (normal ductal structure) no invasion was detected (**Fig2A, left**), at 15 and 18 weeks local invasive CFP+ cells were detected (**Fig2A**) invading into the stroma (**Fig2A,**). CFP reports faithfully for Her2 overexpressing cells as confirmed using double Her2 and CFP IF (>90% Her2+ cells were CFP+; not shown). p38 α/β inhibition with SB203580 stimulated (**Fig2A-D**) invasion and now CFP+ cells were found intravasating (**Fig2B, C and D**). 3D reconstruction of the videos showed unambiguously how individual cells from the ductal pre-malignant lesions (**Fig2B'-C**) enter the lumen of blood vessels (**Fig2C-D**).

The intravasation documented in the movies led to successful dissemination as we found Her2+/CK8/18+ early disseminated cancer cells (eDCCs) detected in the blood, BM and Her2+ eDCCs in lungs of 100% of 14-18 weeks old mice (**Fig2E-G**). Also, systemic inhibition of p38 for 2 weeks significantly increased numbers of early circulating cancer cells (eCCCs) (**Fig2E**), eDCCs in BM (**Fig2F**), and eDCCs in lungs (**Fig2G**). (14. This work is part of a manuscript now

